What is Genentech?
Genentech, a pioneering biotechnology firm headquartered in South San Francisco, California, has been at the forefront of developing innovative therapies for serious medical conditions since its inception in 1976. The company dedicates its efforts to the research and development of biopharmaceuticals, aiming to significantly improve patient outcomes within the global healthcare landscape. Its long-standing commitment to scientific advancement positions it as a key player in the life sciences industry.
How much funding has Genentech raised?
Genentech has raised a total of $100M across 1 funding round:
Unspecified
$100M
Unspecified (1976): $100M with participation from Kleiner Perkins Caufield & Byers
Key Investors in Genentech
Kleiner Perkins Caufield & Byers
Kleiner Perkins is a prominent venture capital firm specializing in early and growth-stage technology and life sciences companies. They provide capital and operational support to founders from seed stages through IPO or acquisition.
What's next for Genentech?
With substantial enterprise-level funding and a recent strategic investment, Genentech is well-positioned for continued expansion and innovation. The company's focus on groundbreaking research and development in biopharmaceuticals suggests a trajectory geared towards scaling its therapeutic pipeline and potentially entering new market segments. This strategic backing will likely fuel further advancements in addressing unmet medical needs and reinforcing its leadership in the biotechnology arena.
See full Genentech company page
